News Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ Continue Reading Previous Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B ProgramNext Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron Related Stories News USAS Building System Listed on the Hong Kong Stock Exchange: A Top-Three Industrial Prefabricated Steel Structure Solution Provider Enters a New Phase in the Capital Markets News DEFSEC Technologies Inc. Announces Full Year Fiscal 2025 Results and Outlook for Fiscal 2026 News The FUTR Corporation Announces Enterprise Agreement with Direct Wholesale Rates to Expand AI-Powered Mortgage, Payments, and Home Concierge Services in the U.S. News Pineapple Financial Appoints Anthony Georgiades to Board of Directors and Special Advisory Committee News Gatekeeper Reports $31.8M Revenue in Fiscal 2025 News FONAR Signs Definitive Agreement for “Take Private” Sale to Acquisition Group Led by CEO
